Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the oral administration of biologic therapeutics. This groundbreaking approach not only enhances patient adherence but also aligns with the growing preference for non-invasive treatment options. With a robust and diversified pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned for significant growth. The company’s commitment to cutting-edge research and development, along with key partnerships, further underscores its potential to make impactful advancements in the pharmaceutical sector.
| Revenue (TTM) | $4.88M |
| Gross Profit (TTM) | $4.88M |
| EBITDA | $-32.24M |
| Operating Margin | -517.00% |
| Return on Equity | -172.20% |
| Return on Assets | -53.00% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $0.35 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | 21.87 |
| EV/Revenue | 7.93 |
| EV/EBITDA | -1.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 893.00% |
| Shares Outstanding | $115.42M |
| Float | $82.33M |
| % Insiders | 4.91% |
| % Institutions | 46.80% |
Volatility is currently expanding
SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming September conferences.
Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~ ~ Appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to Board of Directors ~ SAN JOSE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani's new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately.
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement led by a sovereign wealth fund, along with other new and existing healthcare-focused funds for the purchase and sale of 12,476,637 shares of Rani Therapeutics' Class A common stock at a purchase price of $1.07 per share and pre-funded warrants to purchase 6,214,953 shares of Class A common stock at a purchase price of $1.0699 per pre-funded warrant in a registered direct offering priced at-the-market under Nasdaq rules.
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen –
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RANI and any ticker you trade — then tracks every position and per-strategy win rate.
